- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01508416
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (METRO)
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study
Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone. This association was mainly heightened during the 3 first months of chemotherapy.
Several coagulation abnormalities have been described. Laboratory tests measuring the overall thrombophilic tendency might be useful to assess thrombosis risk.
The aim of this study is to compare thrombin generation by calibrated automated thrombogram during the 3 first cycles of chemotherapy in patients with newly diagnosed MM.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Clermont-ferrand, France, 63000
- CHU de Clermont Ferrand
-
Nancy, France, 54000
- Chu de Nancy
-
Saint Etienne, France, 42055
- Service de Médecine Interne - CHU de Saint Etienne
-
Saint Etienne, France, 42055
- Service de rhumatologie - CHU de Saint Etienne
-
Saint Priest en Jarez, France, 42270
- Service d'hématologie - ICL
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Inscription to medical assurance
- Patients who gave their written consent
- Patients with newly diagnosed Multiple Myeloma required chemotherapy
Exclusion Criteria:
- Patients with renal failure who need to undergo hemodialysis
- Patients with indication for curative anticoagulant therapy
- Patient with 3 month follow-up not possible
- Patient with life expectancy < 6 month
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Patients with Multiple Myeloma
Patients with newly diagnosed Multiple Myeloma required chemotherapy
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
change from baseline in Thrombin generation measure
Délai: day 21
|
change from baseline in Thrombin generation measure
|
day 21
|
change from baseline in Thrombin generation measure
Délai: day 42
|
change from baseline in Thrombin generation measure
|
day 42
|
change from baseline in Thrombin generation measure
Délai: day 63
|
change from baseline in Thrombin generation measure
|
day 63
|
change from baseline in Thrombin generation measure
Délai: day 0
|
change from baseline in Thrombin generation measure
|
day 0
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
image-confirmed venous thromboembolic events
Délai: day 63
|
Estimate the incidence of venous thromboembolic events until day 63
|
day 63
|
change from baseline in TFPI resistance measure
Délai: day 21
|
change from baseline in TFPI resistance measure
|
day 21
|
change from baseline in acquired protein S deficiency measure
Délai: day 21
|
change from baseline in acquired protein S deficiency measure
|
day 21
|
change from baseline in TFPI resistance measure
Délai: day 42
|
change from baseline in TFPI resistance measure
|
day 42
|
change from baseline in TFPI resistance measure
Délai: day 63
|
change from baseline in TFPI resistance measure
|
day 63
|
change from baseline in acquired protein S deficiency measure
Délai: day 42
|
change from baseline in acquired protein S deficiency measure
|
day 42
|
change from baseline in acquired protein S deficiency measure
Délai: day 63
|
change from baseline in acquired protein S deficiency measure
|
day 63
|
change from baseline in TFPI resistance measure
Délai: day 0
|
change from baseline in TFPI resistance measure
|
day 0
|
change from baseline in acquired protein S deficiency measure
Délai: day 0
|
change from baseline in acquired protein S deficiency measure
|
day 0
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Bernard TARDY, MD-PhD, CHU de Saint-Etienne - CIC-EC (CIE3)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies cardiovasculaires
- Maladies vasculaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Maladies hématologiques
- Troubles hémorragiques
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Myélome multiple
- Tumeurs, plasmocyte
Autres numéros d'identification d'étude
- 1108178
- 2011- A01529-32 (Autre identifiant: Afssaps)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .